Soligenix, Inc. (SNGX) Q3 Net Loss Falls To $1.1M; Cash Is $9.0M
Soligenix reported no revenue for Q3 2026, with a net loss of $1.1M, or $0.05 per share, down from $2.5M a year earlier. The company had $9.0M in cash at the end of the quarter. The results follow the termination of the FLASH2 trial and reduced development activities for HyBryte.
How this was made

The 30-second read
Why it matters
The Q3 loss highlights execution risk and may trigger short‑term price decline.
Market read
Quarterly earnings update for a micro‑cap biotech, likely prompting modest price movement.
What to watch
Potential upcoming partnership or licensing deals could offset the loss.
Background
Soligenix provides therapies for rare diseases; recent trial terminations have reduced its pipeline.
Ticker impact
Q3 2026 net loss reported at $1.1M versus $2.5M a year earlier, with cash of $9.0M.
downward pressure as investors price in higher loss and limited cash runway
Quarterly loss more than doubles YoY; no revenue and cash balance modest, likely prompting sell‑side activity.
Market effects
Biotech small‑cap sector may see broader risk‑off sentiment due to weaker earnings.
Limited to US OTC/ Nasdaq micro‑cap investors.
Minimal global impact.
Counterpoint
Long‑term investors may view the cash position as sufficient for upcoming trial milestones.
Key entities
- CompanySoligenix, Inc.
Biotech firm developing treatments for rare diseases.
